Short Term Effect of Liraglutide Versus Vildagliptine on Insulin Secretion and Insulin Sensitivity in Type 2 Diabetes

Sponsor
Yaounde Central Hospital
Study ID
NCT02832999
Phase
PHASE4
Status
Completed

Conditions

Eligibility Criteria

Sex
ALL
Age
21 Years - 70 Years
Healthy Volunteers
Not accepted

Interventions

Study Details

This is a single blind randomised controlled clinical trial in uncontrolled type 2 Diabetes mellitus patients on oral glucose lowering agents, and naive to incretinomimetic. Participants will be randomised in two Arms : arm 1 receiving Liraglutide at 1,2 mg/day and arm 2 Vildagliptine at 100mg/day over 14 days. The two arms will be compared for 14-day changes in insulin secretion and insulin sensitivity.

Key Dates

Start date
Jan 31, 2016
Status verified
Dec 2017
Primary completion
Sep 30, 2016
Completion
Dec 31, 2016

Study Design

Enrollment
14 participants (actual)
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT

Arms

  • Experimental: sub cutaneous liraglutide
    once daily add-on subcutaneous injection of Liraglutide at 0.6mg/day for 1 week increased to 1.2mg the second week
  • Active Comparator: Oral Vildagliptin
    Once daily oral 100mg of Vildagliptine for two weeks

Primary Outcome Measure

Insulin sentivity [ Time Frame: 2 weeks ]

Related Studies